Trial Profile
CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer: a Feasibility Phase II Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary)
- Indications Early breast cancer
- Focus Adverse reactions
- 18 Sep 2023 Planned End Date changed from 25 Mar 2021 to 31 Dec 2023.
- 18 Sep 2023 Planned primary completion date changed from 25 Mar 2021 to 31 Dec 2023.
- 29 Jan 2020 Planned End Date changed from 31 Dec 2019 to 25 Mar 2021.